



HBM Biopharma Summit

22nd–24th September 2024
Park Hyatt Zurich

HBMPartners

HBM Healthcare
Investments



WELCOME

For more than a decade, HBM hosted yearly conferences, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry.

NETWORKING

With networking being a key element of the HBM Biopharma Summit, we have enough time reserved for you to interact with other participants.

EXPERT PANEL

Melanie Senior, Biopharma Reporter & Science Strategy Writer (moderator)

Interactive dialogue with Vlad Coric, Niels Emmerich, Richard Girling and Michal Preminger.



To the Event Website:

CONFERENCE PROGRAM

September 22

- 16:00 REGISTRATION & WELCOME DESK Ballroom Foyer
- 18:30 TRANSFER TO DINNER LOCATION Meet in Lobby
- 18:45 INFORMAL DINNER AT RESTAURANT SEEROSE
Restaurant Seerose, Seestrasse 493, 8038 Zürich
- 22:00 ONWARDS GROUP TRANSFERS TO PARK HYATT HOTEL

September 23 Ballroom Foyer & Ballroom

- 07:15 REGISTRATION & WELCOME COFFEE

COMPANY PRESENTATIONS

- | | | | |
|-------|--------------------|-------|----------------------|
| 07:45 | Ignis Therapeutics | 10:15 | Orano Med |
| 08:00 | Sobi | 10:30 | Sanofi |
| 08:15 | Abbvie | 10:45 | Chemomab |
| 08:30 | Dren Bio | 11:00 | Argenx |
| 08:45 | Royalty Pharma | 11:15 | ADARx |
| 09:00 | Johnson & Johnson | 11:30 | Neurelis |
| 09:15 | Numab Therapeutics | 11:45 | Alumis |
| 09:30 | Insmed | 12:00 | Odyssey Therapeutics |
| 09:45 | Biohaven | 12:15 | Arrakis |
| 10:00 | Zymeworks | | |

NETWORKING LUNCH

11:30 UNTIL 13:30

September 23 Ballroom

CONFERENCE

- 13:30 **Keynotes**
- David Redfern, GSK, President Corporate Development
 - Michel Lagarde, Thermo Fisher Scientific, Executive Vice President & Chief Operating Officer

New Frontiers in Next-Gen Cell Biology

Mostafa Ronaghi, Cellanome, Cofounder, Executive Chairman

Building the first Row Commercialization Platform for Biopharma

Jean-Michel Lespinasse, Swixx BioPharma, CEO

The Healthcare M&A Environment

Richard Girling, Centerview Partners, Partner

Panel

State of the Industry

Moderated by Melanie Senior, Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO

- 18:40 **SHORT WALK TO DINNER LOCATION**

Easy 15 minute walk along river and old town

- 19:00 **COCKTAILS & DINNER ZUNFTHAUS ZUR MEISEN**

Zunfthaus zur Meisen, Münsterhof 20, 8001 Zürich

- 22:00 **WALK BACK TO PARK HYATT HOTEL**

INFORMAL GATHERING IN ONYX BAR, PARK HYATT HOTEL

(please bring your conference badge to the bar)

September 24 Ballroom Foyer & Ballroom

07:15 COFFEE & CROISSANTS

COMPANY PRESENTATIONS

07:45	eGenesis	11:45	Y-mAbs Therapeutics
08:00	Karius	12:00	Aphaia
08:15	Fore Biotherapeutics	13:00	Biontech
08:30	Astellas	13:15	Perspective Therapeutics
08:45	Molecular Partners	13:30	Real Endpoints
09:00	Vicore Pharma	13:45	Traverse Therapeutics
09:15	Cellanome	14:00	Neuron23
09:45	ALX Oncology	14:15	Arcutis Biotherapeutics
10:00	Mineralys	14:30	Mahzi Therapeutics
10:15	Denali	14:45	Abivax
10:30	Nikang Therapeutics	15:00	MeiraGTx
10:45	Biomea Fusion	15:15	Basilea Pharmaceutica
11:00	Orna Therapeutics	15:30	TrueMed Therapeutics
11:15	Fangzhou	15:45	Atara Biotherapeutics
11:30	Monte Rosa Therapeutics	16:00	Shenzhen Chipscreen
		16:15	BioInvent

NETWORKING LUNCH

11:30 UNTIL 13:30

SPEAKERS



Please scan QR code for full bio and/or company website

DAVID REDFERN

President Corporate Development GSK

David was appointed President Corporate Development of GSK in May 2008 and is responsible for corporate development and the leadership of the execution of all GSK's business development activities. He is a member of the GSK Leadership Team and reports to the CEO. In addition to his current role, David is Chairman of ViiV Healthcare Ltd. ViiV was created in 2010 and is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research, development and commercialisation of medicines to treat HIV and has global sales of £6billion.

MICHEL LAGARDE

Executive Vice President &
Chief Operating Officer Thermo Fisher Scientific

Michel was named Executive Vice President in September 2019 and became Chief Operating Officer in January 2022. Michel has responsibility for Thermo Fisher's Pharma Services, Customer Channels, BioProduction, Analytical Instruments and Clinical Research Groups, as well as the company's Corporate Accounts function and Chief Medical Office. He joined the company as Senior Vice President and President of the Pharma Services Group through the acquisition of Patheon in 2017.



Please scan QR code for full bio and/or company website

SPEAKERS



RICHARD GIRLING

Partner, Centerview Partners

Richard Girling is one of Europe's leading healthcare bankers with over 30 years of experience. Mr. Girling has advised on many of the largest global healthcare transactions including: AstraZeneca in its \$39bn acquisition of Alexion and its \$15bn acquisition of MedImmune, Sanofi's \$73bn acquisition of Aventis and its \$1.9bn acquisition of Kadmon, the \$24bn LBO of Alliance Boots plc and its subsequent \$27bn sale to Walgreens and Vifor Pharma on its \$12bn sale to CSL. Mr. Girling established the European business of Centerview Partners in London in 2009. Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions.



Please scan QR code for full bio and/or company website

JEAN-MICHEL LESPINASSE

Chief Executive Officer, Swixx Biopharma

Jean-Michel Lespinasse is the CEO of Swixx Biopharma, a leading pharmaceutical agent specializing in Rare Diseases, Oncology, Hematology, Vaccines, and Specialty Pharmaceuticals. Since the company's inception in 2015, Jean-Michel has grown Swixx into an organization of over 1,500 employees and 1,1 Billion Euros net sales, with a presence spanning from Central and Eastern Europe, to CIS, and Middle East. Under his leadership, in June 2024, Swixx successfully acquired Biopas in Latin America, further expanding its global footprint.



Please scan QR code for full bio and/or company website



MOSTAFA RONAGHI

Co-Founder and Executive Board Member Cellanome

Dr. Ronaghi is a scientist-entrepreneur, inventor, investor, company-founder, executive and director. He is the co-founder and executive Board Member at Cellanome. Most recently, he was Chief Executive Officer at Dynamics Special Purpose Corp, a SPAC company that acquired Senti Bio. Prior to that, he was Chief Technology Officer, Senior Vice President and member of the Executive Leadership Team at Illumina (Nasdaq: ILMN) from 2008 to 2021. While at Illumina, in 2016, Dr. Ronaghi co-founded GRAIL, a next-gen liquid biopsy platform for cancer detection. He also started Illumina's Research & Technology Development group, and co-founded the Illumina Accelerator Program in 2014, one of the most successful accelerator programs in the industry. Prior to Illumina, Dr. Ronaghi was Principal Investigator at the Stanford Genome Technology Center from 1999 to 2008.



Please scan QR code for full bio and/or company website

MELANIE SENIOR

Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms

I write about biopharma R&D, strategy, investment and market access for the Nature portfolio, Evaluate Pharma and Celine. I also support companies and associations with market positioning and white papers. My career began at the London Financial Times; I then became Bureau Chief, Europe, for Elsevier Business Intelligence. I worked as a reimbursement and pricing analyst for Real Endpoints in the US and was part of EY Life Sciences' thought leadership team between 2014-2017. My education includes a First Class degree in Natural Sciences (biochemistry) from Cambridge University and post-graduate qualifications in Sports Physiology & Nutrition (St Mary's University) and in International Health Technology Assessment (University of Sheffield). I'm a keen runner, cyclist and swimmer (but not a triathlete). At the moment, I'm based in London, UK.



Please scan QR code for full bio and/or company website

PARTICIPANTS

COMPANY

	COMPANY	NAME	
A	Abbvie	Niels Emmerich	
	Abivax	Marc de Garidel	
	ADARx Pharmaceuticals	Zhen Li	
	Adrenomed	Richard Jones	
	Alumis	Martin Babler	
	ALX Oncology	Jason Lettmann	
	ALX Oncology	Jaume Pons	
	Aphaia	Frank Morich	
	Arcutis Biotherapeutics	Frank Watanabe	
	Argenx	Arjen Lemmen	
	Arrakis Therapeutics	Michael Gilman	
	ArvicBio	Bruno Strigini	
	Asceneuron	Abbas Hussain	
	Astellas	Hiro Usuda	
	Astr Partners	Jonathan Fassberg	
Atara Biotherapeutics	Pascal Touchon		
Auretas	Matthias Rathgen		
Avenzo Therapeutics	Athena Countouriotis		
B	BainCapital	Ricky Sun	
	Basilea Pharmaceutica	David Veitch	
	Bigger Advisory	Philipp Bigger	
	Biohaven	Vlad Coric	
	Biolnvent	Martin Welschof	
	Biomea Fusion	Thomas Butler	
	Biomea Fusion	Ramses Erdtmann	
	Biomea Fusion	Juan Pablo Frias	
	Biontech	Ryan Richardson	
	Biopas	Pascal Forget	
	Blueprint Medicines	Andrew Kim	
	Brahma	Niccolò Colussi	
	Bryan Garnier	Bruno Bulic	
	C	Cellanome	Jasmine Pritchard
		Cellanome	Mostafa Ronaghi
Centerview Partners		Alexander Elias	
Centerview Partners		Luca Gilotti	
Centerview Partners		Richard Girling	
Chemomab		Adi Mor	
CIC		Arnaud Cadart	
Clinigen Group		Jerome Charton	
Clinigen Group		Nihad Hasagic	
Credit Suisse		Salvatore Gambone	
Cure Everlife		Rica Oberoi	

COMPANY

	COMPANY	NAME
	Cure Ventures	Richard J. Lim
	Cytea Bio	Eric Falcand
	Cytokinetics	Robert Blum
D	Denali Therapeutics	Alexander Schuth
	Dren Bio	Amit Mehta
	Dren Bio	Nenad Tomasevic
E	eGenesis	Mike Curtis
F	Fangzhou	Feng Zhou
	Fangzhou	Yuming Zou
	Federated Hermes	Thomas Brakel
	Federated Hermes	Fabrice Di Giusto
	Fore Biotherapeutics	Bill Hinshaw
	Friedrich-Alexander University FAU	Ricardo Grieshaber-Bouyer
	Genioo	Frédéric Brunner
G	Gilde Healthcare	Joep Muijers
	GISEV Family Office	Matteo Alicanti
	Goldman Sachs	Josh Richardson
	GSK	David Redfern
	Hamberg	Nicolas Oltramare
H	HBM Genomics	Saeid Akhtari
	HBM Healthcare Investments	Germano Giuliani
	HBM Healthcare Investments	Hans Peter Hasler
	HBM Partners	Alexander Asam
	HBM Partners	Priyanka Belawat
	HBM Partners	Francesco D'Amico
	HBM Partners	Matthias Fehr
	HBM Partners	Ulrich Geilinger
	HBM Partners	Mirjam Heeb
	HBM Partners	Thomas Heimann
	HBM Partners	Michael Jasulavic
	HBM Partners	Romain Kooger
	HBM Partners	Dominique Küttel
	HBM Partners	Chandra Leo
	HBM Partners	Gavin MacGregor
	HBM Partners	Henri B. Meier
	HBM Partners	Asun Monfort
	HBM Partners	Shirin Schneeberger
HBM Partners	Ivo Stajjen	
HBM Partners	Erwin Troxler	
HBM Partners	Andreas Wicki	

COMPANY**NAME**

I	Ignis Therapeutics	Eileen Long	
	Immatics	Carsten Reinhardt	
	Insmad	Will Lewis	
J	Johnson & Johnson	Michal Preminger	
K	Karius	Sivan Bercovici	
L	Lundbeck	Keld Flintholm Jorgensen	
M	Mahzi	Rob Anstey	
	Marshall Wace	Robin David Boldt	
	Marwees International	Peter Berweger	
	MA7	Michele Brotugno	
	MA7	Atila Koc	
	Meira GTx	Zandy Forbes	
	Meliora Capitol	Thierry Serero	
	MGG Capital	Dror Schwartz	
	Mineralys	Jon Congleton	
	Molecular Partners	Patrick Amstutz	
	Monte Rosa Therapeutics	John Castle	
	N	Nature Biotechnology	Melanie Senior
		Neurelis	Craig Chambliss
Neuron23		Nancy Stagliano	
NiKang Therapeutics		Zhenhai Gao	
Norgine		Peter Stein	
Novartis		Jesus Baena	
Novartis Venture Fund		Anja Koenig	
Nuance Biotech		Mark Glotter	
Numab Therapeutics		Roland Helfenstein	
Numab Therapeutics		David Urech	
O		Oculus	Tony Rosenberg
		Odyssey Therapeutics	Gary Glick
		OM Pharma	Etienne Jornod
	Orano Med	Julien Dodet	
	OrbiMed	Dina Chaya	
	OrbiMed	Ashiya Mona	
	Orna Therapeutics	Brian Shuster	
P	Partners Group	Jean Ghabache	
	Peel Hunt	Miles Dixon	
	Peel Hunt	Markuz Jaffe	
	Perspective Therapeutics	Thijs Spoor	
	Pharvaris	Wim Souverijns	
	PKB Private Bank	Roland Eberhard	
	Pureos	Martin Münchbach	

COMPANY**NAME**


Q	Quan Capital	Marietta Wu
R	Real Endpoints	Jeffrey Berkowitz
	Roche	Céline Bouquet
	Roche	Marc Christian Buser
	Rock Springs Capital	Mark Bussard
	Rothschild & Co.	Jeremy Wiseman
S	Royalty Pharma	Jim Reddoch
	Sai	Krishna Kanumuri
	Sanofi	Monika Vnuk
	SBTech Global Consulting	Shmulik Berkovich
	Shenzhen Chipscreen Biosciences	Xian-Ping Lu
	Sidley Austin	Mehdi Khodadad
	Sobi	Guido Oelkers
	Sobi	Daniel Rankin
	SR One Capital Management	Iqbal Mufti
	Suvretta Capital Management	Kishen Mehta
	Swiss Biotech Association	Michael Altorfer
	Swixx Biopharma	Jean-Michel Lespinasse
	Swixx Biopharma	Stuart Swanson
Syncona	John Tsai	
T	Thermo Fisher Scientific	Michel Lagarde
	Travere Therapeutics	Eric Dube
	Travere Therapeutics	Giovanni Stropoli
	TrueMed Therapeutics	Idan Berkovich
U	UCB	David Flint
V	Vascudyne	Claude Richard Amos
	Vemeer Partners	Simon Barrell
	Venrock	Nimish Shah
W	Vicore Pharma	Ahmed Mousa
	Wellington Management	Nilesh Kumar
Y	Yaya Capital	Tiago Menezes
	Yaya Capital	Marcus Pratini
	Y-mAbs Therapeutics	Thomas Gad
	Y-mAbs Therapeutics	Michael Rossi
	Ysios Capital	Joël Jean-Mairet
Z	Zymeworks	Lindsey Foulkes
	Zymeworks	Kenneth Galbraith
	Zymeworks	Shrinal Inamdar

PRESENTING COMPANIES

These companies will give each a 15 minute presentation.



LOCATIONS



ZUNFTHAUS ZUR MEISEN

Münsterhof 20
8001 Zurich



Historical house from the middle age, located in the middle of the city directly by the Limmat, in a magnificent building steeped with history from the Middle Ages.

PARK HYATT ZURICH

Beethovenstrasse 21
8002 Zurich



Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town.

RESTAURANT SEEROSE

Seestrasse 493
8038 Zurich



Welcome to Zurich's most beautiful lake shore. Here you'll find a maritime world of its own.